ClinicalTrials.gov
Cure8 trial brief
Why This Matters
This trial tests whether the common sweetener sucralose alters the gut microbiome in people with Crohn’s disease in remission compared with healthy volunteers.
Diet and additives are a modifiable exposure that could influence gut bacteria and potentially affect symptoms or disease course, so patients and clinicians may be interested in the study question.
Who Should Pay Attention
Adults with Crohn’s disease in remission; researchers and clinicians studying diet–microbiome interactions in IBD; people interested in effects of non-nutritive sweeteners.
Study Snapshot
Story typeClinical Reference
Trial phaseNA
Enrollment40 participants
Study statusRecruiting
Source depthTrial registry record
What To Know
This is a registered interventional study testing whether short-term exposure to the non-nutritive sweetener sucralose changes the gut microbiome in adults with Crohn’s disease (CD) in remission compared with healthy controls.
The trial enrolls adults 18–70, involves a 14-day baseline period with removal of all non-nutritive sweeteners, followed by 21 days of sucralose (2 sachets/day; 2.5 mg/kg/day), and collects stool, urine, and blood before and after each phase. The primary outcome is change in the fecal microbiome measured by metagenomic analysis.
Planned enrollment is ~40 participants, and key exclusions include recent antibiotic use, active malignancy, ostomy, symptomatic strictures, recent changes in IBD medication, and pregnancy.
If you have Crohn’s disease and are in clinical remission, this study is testing a dietary exposure (sucralose) below the accepted daily intake to look for microbiome effects; it does not test clinical outcomes or treatments for IBD.
Keep In Mind
This is a recruiting interventional trial record (ClinicalTrials.gov). The entry describes study design and planned sample collection but does not report results; interpret any future reported findings in light of the small sample size and short exposure period.
Source Details
Review the original publication for the complete reporting, methods, and context.
Clinical trial
Evidence type derived from source or registry metadata.
PublicationClinicalTrials.gov
SponsorUniversity Hospitals Cleveland Medical Center
Trial IDNCT07769437
Study typeInterventional
Trial phaseNA
Enrollment40 participants
Indexed viaClinicalTrials.gov
Source typeTrial registry record
PublishedAug 18, 2026, 12:00 AM
Content availableTrial registry record
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Cranberry and Gut Health in Crohn's Disease
People with Crohn’s disease often have disrupted gut microbiomes; this trial tests a food-based approach (cranberry powder) that could potentially encourage beneficial bacteria and reduce inflammation, which is of direct...
Study explores microbiome reboot to prolong effect of Crohn's disease therapy
This study tests whether a ‘microbiome reboot’ — using exclusive enteral nutrition followed by fecal microbiome transfer — can make the beneficial microbiome changes last longer and help keep Crohn’s disease in...
Microbiome shift linked to Crohn's disease remission sparks clinical study on new therapy
This reports a potential new way to extend remission after exclusive enteral nutrition by combining diet with fecal microbiome transfer—an approach that targets the gut microbiome rather than adding drugs. If effective,...